The 2nd Joint Scientific Consultation request period 2025 – a unique opportunity?
Author: Sebastian Vinzens, Senior Medical Writer, Germany Joint Scientific Consultations (JSCs) are primarily designed to provide critical input into […]
Highlights from DIA Europe 2025
Author: Univ.-Prof. Dr. Matthias P. Schönermark, Chief Strategy Officer at Kintiga At DIA Europe 2025, held from March 18-20 in
Reforming Drug Price Regulation: A Critical Imperative for Pharmaceutical Companies in Germany
Reforming Drug Price Regulation: A Critical Imperative for Pharmaceutical Companies in Germany Author: Dr. Lara Kleinesudeik, Market Access Manager, Germany
European Commission proposes EU Joint Procurement in draft Critical Medicines Act
Author: Sebastian Vinzens, Senior Medical Writer, Germany On 11 March 2025, the European Commission (EC) proposed the Critical Medicines Act
Reflections on the 2025 World Evidence, Pricing and Access Conference in Amsterdam
Author: Jo Wallis The 2025 World Evidence, Pricing and Access (EPA) Congress in Amsterdam brought together over 1,500 attendees from
Rare Disease Day: A Brief Introduction to the European Medicines Agency Orphan Designation
2025 marks 25 years since the Orphan Medicinal Products Regulation (EC) No 141/2000) was introduced by the EMA, offering Health
Kintiga™ to be officially launched at the World EPA Congress in Amsterdam, 5-6 March 2025
Kintiga™ to be officially launched at the World EPA Congress in Amsterdam, 5-6 March 2025 Under the new shared
Paving the Way for Rare Disease Day: The Special Situation of Orphan Drugs in the New EU HTA Framework
Since January 2025, new innovative drugs have been subject to the European Health Technology Assessment (EU HTA). Initially, the procedure
Press Release – The MAP Group Unites Three Companies Under One New Brand Name, KINTIGA
– The new name, Kintiga, reflects the company’s bold vision to be the indispensable European strategic partner for health technology
Case Study: EU5 – Commercial Evaluation of a Licensed Product for the Five Major EU Markets
Client Challenge Our client had received an offer for a marketing license for a Phase III product for the 5 major
